Barclays Initiates Coverage of Edwards Lifesciences at Overweight
Fintel reports that on October 7, 2026, Barclays initiated coverage of Edwards Lifesciences (NYSE:EW) (SWX:EW) with a Overweight recommendation.
Edwards Lifesciences Corporation, based in the United States, operates primarily in the healthcare sector, focusing on the development and marketing of innovative medical solutions for structural heart disease and critical care monitoring. The company is known for its transcatheter aortic valve replacement systems and precision hemodynamic monitoring. On October 7, 2026, the company's stock closed at $85.78, following a pre-action close of $86.48 on October 6, 2026. Over a one-week period, the stock experienced a price change of -0.63% from a baseline close of $86.32 on September 30, 2026. Over a one-month period, the stock saw a price change of -4.58% from a baseline close of $89.90 on September 4, 2026.
The current consensus target mean for Edwards Lifesciences was $101.84 as of October 2, 2026, representing an implied change of +18.72% from the stock's valuation. This mean target remains unchanged from the prior consensus target mean of $101.84 recorded on September 15, 2026, reflecting a consensus target revision of 0.00%. The current consensus target median was reported at $103.02 on October 2, 2026. In terms of broader analyst sentiment, the current recommendation period as of September 1, 2026, shows a total of 40 recommendations, consisting of 13 strong buy, 18 buy, and 9 hold ratings. This represents a positive recommendation percentage of 77.5% and a hold percentage of 22.5%. In the prior period as of August 1, 2026, the total recommendation count was also 40, with 13 strong buy, 17 buy, and 10 hold ratings, representing 75.0% positive and 25.0% hold recommendations.
In other recent analyst activity, BTIG reiterated its Buy rating for Edwards Lifesciences on September 11, 2026, maintaining its previous Buy rating. Looking at financial performance, the company reported its latest earnings on July 23, 2026, with an actual EPS of 0.78, which exceeded the estimated EPS of 0.7627, representing an EPS surprise of +2.27%. The actual revenue for the quarter was $1,741,000,000.00, compared to an estimated revenue of $1,751,169,280.00. Edwards Lifesciences is scheduled to release its upcoming earnings on November 4, 2026, during the after market close session.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Overweight | initiated coverage | |
| September 11, 2026 | BTIG | Buy | Buy | reiterated |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.